Clinical trials: Generations
BCL2 Gene mRNA Overexpression
Validation of Useful Markers Generated by Next Generation Bio-data Based Genome Research and Cohort Study
Multiple biomarker development through validation of useful markers generated by next generation bio-data based genome research and cohort study
- Trial name
- miRNA_Chip (NCT02807896)
- Where
- South Korea
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- CHANGHEE LEE
Symptomatic Severe Aortic Stenosis
Portico Next Generation Approval Study
The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the…
- Trial name
- NCT04011722
- Testing
- Portico™ NG (Navitor) Valve and FlexNav™ Delivery System, Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System
- Where
- 28 sites in United States, Australia and 3 more
- Volunteers
- 333 people
- Sponsor
- Abbott Medical Devices
Chronic Spontaneous Urticaria
Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)
Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to escalate/switch current treatment to remibrutinib.
- Trial name
- NCT07642557
- Where
- Germany
- Volunteers
- 470 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Adults With Type 2 Diabetes
The purpose of the study is to assess the safety and efficacy of a next generation automated insulin delivery algorithm in adults with type 2 diabetes aged 16-70 years old
- Trial name
- NCT07039981
- Testing
- Omnipod M system
- Where
- 2 sites in New Zealand
- Volunteers
- 48 people
- Sponsor
- Insulet Corporation
Chronic Spontaneous Urticaria (CSU)
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily [b.i.d.] by mouth [p.o.]) compared to dupilumab (600 mg loading dose administered…
- Trial name
- RECLAIM (NCT06868212)
- Testing
- Remibrutinib, Dupilumab
- Where
- 121 sites in United States
- Volunteers
- 409 people
- Sponsor
- Novartis Pharmaceuticals
de Novo Lesions in Native Coronary Arteries
First in Man Trial - BIOSOLVE-I
First in Man Trial with the drug eluting absorbable metal scaffold. To assess safety
- Trial name
- BIOSOLVE-I (NCT01168830)
- Testing
- AMS-3.0
- Where
- 6 sites in Belgium, Germany and 2 more
- Volunteers
- 46 people
- Sponsor
- Biotronik AG
Pulmonary Fibrosis
A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device
This study is open to adults aged 18 years and older who have pulmonary fibrosis with or without a known cause (or other forms of pulmonary fibrosis).
- Trial name
- NCT05670587
- Testing
- A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Ultrasound Exam in Emergency/Medical Care
Venue Ultrasound Evaluation - Israel
The study purpose is to collect images and user feedback from the Next Generation Venue Ultrasound system, components, and accessories under clinical conditions, as required for device development and optimization.
- Trial name
- NCT03861663
- Testing
- Ultrasound
- Where
- Israel
- Volunteers
- 53 people
- Sponsor
- GE Healthcare
Cataract
Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus
The purpose of this study is to determine the safety and efficacy of Next Generation Ophthalmic Irrigating Solution (NGOIS) compared to BSS Plus for use during cataract extraction and intra-ocular lens (IOL) implantation.
- Trial name
- NCT00333268
- Testing
- Next Generation Ophthalmic Irrigating Solution (NGOIS), BSS Plus
- Where
- United States
- Volunteers
- 369 people
- Sponsor
- Alcon Research
Coronary Artery Disease
Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System
A prospective, randomized, active-control, multi-center clinical trial comparing the safety and efficacy of the Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS) to that of the commercially available Resolute…
- Trial name
- DIRECT II (NCT01788150)
- Testing
- Coronary Stenting
- Where
- 18 sites in Belgium, Czechia and 5 more
- Volunteers
- 159 people
- Sponsor
- Svelte Medical Systems, Inc.
Pulmonary Nodules
Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules
AnchorDx is using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS) to develop a blood-based assay for differentiating benign and malignant pulmonary nodules early.
- Trial name
- NCT03651986
- Testing
- ctDNA methylation analysis by NGS
- Where
- 23 sites in China
- Volunteers
- 10,560 people, healthy volunteers welcome
- Sponsor
- AnchorDx Medical Co., Ltd.
Total Laryngectomy
Long Term Use of the Provox Vega 22.5
The purpose of this study was to investigate the long-term feasibility of the new Provox Vega 22.5 voice prosthesis (outer diameter of 22.5 French) and its insertion system (SmartInserter) in laryngectomized patients who…
- Trial name
- NCT00884910
- Testing
- Provox Vega voice prosthesis 22.5 Fr
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- Atos Medical AB
Solid Tumor, Adult, Oncology
POA Prospective Repository
This repository is a multi-center, outcomes study designed to collect data on the demographics, presentation, diagnosis, treatment, cost of associated care, quality of life, and outcomes of subjects utilizing Caris Molecular…
- Trial name
- NCT03324841
- Testing
- Caris MI Profiling
- Where
- 11 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- Caris Science, Inc.
Computed Tomography
Next Generation CT System
The purpose of the study is to collect data to evaluate utility of a next generation CT system in a clinical setting.
- Trial name
- NCT06769594
- Testing
- Investigational CT Scan
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- GE Healthcare
Non-Small Cell Lung Cancer
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Trial name
- NCT06093503
- Testing
- Telisotuzumab Vedotin, Osimertinib, Cisplatin
- Sponsor
- AbbVie
Incontinence, Urge
T-DOC® NXT Clinical Investigation
Assessing the Performance, Safety and Usability of our Next Generation T-DOC® NXT Catheter for Performing Urodynamic Studies
- Trial name
- NCT03615001
- Testing
- TDOC NXT
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Laborie Medical Technologies Inc.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Effectiveness and Safety Study of the Next-Generation DexCom™ SEVEN® Continuous Glucose Monitoring System
The purpose of this study is to evaluate the safety and effectiveness of the next-generation DexCom SEVEN Continuous Glucose Monitoring System (SEVEN.2 System) when worn for up to 7-days by subjects >18 years-old with diabetes…
- Trial name
- NCT00722241
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- DexCom, Inc.
Healthy
A Study of LY3848575 in Healthy Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3848575 when administered either intravenously or subcutaneously in single ascending or multiple doses in healthy non-Japanese and first generation…
- Trial name
- NCT05727072
- Testing
- LY3848575
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Advanced Non-hematologic Malignancies
A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
This is an open-label, multicenter, phase 1, dose escalation study of IXAZOMIB. The primary purpose of this study is to determine the safety profile, establish the maximum tolerated dose, and inform the phase 2 dose of IXAZOMIB…
- Trial name
- NCT00830869
- Testing
- IXAZOMIB
- Where
- 7 sites in United States, Canada
- Volunteers
- 116 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia
PICAROS - Acalabrutinib RWE on 1L CLL in Spain
This is a multicenter non-interventional study (NIS) of patients with CLL treated with first-line acalabrutinib according to routine clinical practice in Spain.
- Trial name
- PICAROS (NCT05999877)
- Where
- 49 sites in Spain
- Volunteers
- 315 people
- Sponsor
- AstraZeneca